bioAffinity Technologies, Inc. (BIAF) AI Stock Summary

Snapshot

bioAffinity is a tiny diagnostics company selling its CyPath Lung cancer test, with FY2025 revenue of $6.2M, down 34% from a smaller prior-year base, and a net loss of $14.9M. It burns about $9.4M a year in free cash flow against just $6.4M in cash, giving a cash runway of roughly 3.3 months. The company has repeatedly issued shares and warrants to raise cash, and its auditor has issued a going-concern warning.

What's Happening Right Now

• Fri 28th Aug '26 · Delisting risk: Nasdaq notified BIAF on July 30, 2026 that it's out of compliance with the $1.00 minimum bid price rule, and because of a prior reverse split the company doesn't get the usual 180-day grace period; it's appealing to a Nasdaq panel.
• Thu 27th Aug '26 · Registration: Registered 1.71M shares for sale on Form S-3.
• Thu 20th Aug '26 · Reverse split: BIAF executed a 1-for-15 reverse stock split effective August 24, 2026, primarily to try to regain Nasdaq compliance, leaving about 592,373 shares outstanding post-split.
• Fri 14th Aug '26 · Offering: Raised $3.94M in gross proceeds through a private placement (PIPE), with warrants over 1.71M shares.
• Fri 7th Aug '26 · Earnings: Q2 2026 revenue rose 19% YoY to $1.5M on a 216% jump in CyPath Lung test volume, and the net loss narrowed to $3.4M from $4.1M, though cash stood at just $2.4M after a $3.2M offering.
• Thu 30th Jul '26 · Partnership: On July 30, 2026, BIAF announced a collaboration with Pictor, Inc. to co-develop diagnostic tests for asthma and COPD, aiming to launch them as lab-developed tests.
• Tue 30th Jun '26 · ATM sale: Sold $1.20M of stock / 8K shares through its at-the-market program.
• Fri 12th Jun '26 · Going concern: In a June 12, 2026 S-1 filing to raise ~$3.4M, BIAF disclosed only $3.1M in cash and a $72.2M accumulated deficit, and its auditor issued a going-concern warning tied to the company's ability to keep operating without more capital.

Ownership

Institutions hold 8.8% of shares, and insiders hold essentially none (0.0%).

Bottom Line

BIAF is a distressed micro-cap: revenue is shrinking, losses far exceed revenue, and cash on hand covers only about three months of burn. The company has done two reverse splits in the past year and repeatedly sold new shares and warrants just to stay funded, on top of a formal going-concern warning from its auditor. CyPath Lung test sales are genuinely growing fast, which is the one bright spot, but nothing here changes the fact this is a company fighting to keep the lights on.